- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00759564
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
An Open-label, 2-way Crossover Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Iv Cp-70429 And Oral Pf-03709270 In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Bruxelles, Belgia, 1070
- Pfizer Clinical Research Unit
-
-
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46260
- Centurion Clinical Research
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Subjects must meet one of the following renal function categories:
- Normal renal function (CLcr >80 mL/min).
- Mild renal impairment (CLcr >50 and <80 mL/min).
- Moderate renal impairment (CLcr >30 and <50 mL/min).
- Severe renal impairment (CLcr <30 mL/min).
Exclusion Criteria:
Women who are pregnant or nursing or women who are of childbearing potential. History of clinically significant allergies, including seasonal allergies, and especially drug hypersensitivity including known allergies to components of the study drug formulation, penicillin, carbapenems and/or cephalosporin antibiotics (eg, amoxicillin, amoxicillin/clavulanate, ampicillin, cefadroxil, cephalexin, cefaclor and cefixime).
Subjects should not have evidence of a history of the following:
- normal renal function: clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological or allergic disease.
- renal impairment: any clinically significant (hepatic, cardiac or pulmonary or subjects with acute nephritic syndrome) diseases (except diabetes). Stable co-morbid disease where it is unlikely that the disease and medication will alter the outcome of the study will be allowed.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: IV CP-70,429 and cross over to PF-03709270
|
Study Periods 1 and 2 will be separated by a minimum of 14 days.
In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following CP-70,429 Intravenous Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
PF-03709270 is an oral prodrug of CP-70,429.
Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429.
Cmax of CP-70429 following CP-70,429 intravenous dose was reported.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-70429 Following CP-70,429 Intravenous Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-70429 Following CP-70,429 Intravenous Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)] of CP-70,429 Following CP-70,429 Intravenous Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
It is obtained from AUC (0-t) plus AUC (t-inf).
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Renal Clearance (CLr) of CP-70429 Following CP-70,429 Intravenous Dose
Tidsramme: 0 (pre-dose), 0 to 6, 6 to 12, 12 to 24 hours post-dose
|
Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).
|
0 (pre-dose), 0 to 6, 6 to 12, 12 to 24 hours post-dose
|
Maximum Observed Plasma Concentration (Cmax) of CP-70429 Following PF-03709270 Oral Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
PF-03709270 is an oral prodrug of CP-70,429.
Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429.
Cmax of CP-70429 following CP-70,429 intravenous dose was reported.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of CP-70429 Following PF-03709270 Oral Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of CP-70429 Following PF-03709270 Oral Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Area under the plasma concentration time-curve from zero (pre-dose) to the time of last measured concentration (AUClast).
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)] of CP-70429 Following PF-03709270 Oral Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
AUC (0-inf) is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
It is obtained from AUC (0-t) plus AUC (t-inf).
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Renal Clearance (CLr) of CP-70429 Following PF-03709270 Oral Dose
Tidsramme: 0 (pre-dose), 0 to 6, 6 to 12, 12 to 24 hours post-dose
|
Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Ae) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).
|
0 (pre-dose), 0 to 6, 6 to 12, 12 to 24 hours post-dose
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Terminal Elimination Half Life (t1/2) of CP-70429 Following CP-70,429 Intravenous Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Terminal Elimination Half Life (t1/2) of CP-70429 Following PF-03709270 Oral Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Terminal elimination half-life is the time measured for the plasma concentration to decrease by one half.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Clearance (CL)
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
It was calculated by dividing given intravenous dose by AUC inf.
AUC inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
It is obtained from AUC (0-t) plus AUC (t-inf).
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Apparent Oral Clearance (CL/F)
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
It was calculated by dividing the given oral dose by AUCinf.
AUC inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
It is obtained from AUC (0-t) plus AUC (t-inf).
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Duration of Plasma Concentrations of CP-70429 Exceeding 0.5 Microgram Per Milliliter Following Intravenous Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 microgram per milliliter (mcg/mL) at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile.
If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Duration of Plasma Concentrations of CP-70429 Exceeding 0.5 Microgram Per Milliliter Following PF-03709270 Oral Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile.
If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Duration of Plasma Concentrations of CP-70429 Exceeding 1.0 Microgram Per Milliliter Following Intravenous Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Duration was calculated by subtracting the time at which the plasma concentrations exceeded 1.0 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 1.0 mcg/mL at the descending part of the profile.
If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Duration of Plasma Concentrations of CP-70429 Exceeding 1.0 Microgram Per Milliliter Following PF-03709270 Oral Dose
Tidsramme: 0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Duration was calculated by subtracting the time at which the plasma concentrations exceeded 0.5 mcg/mL at the ascending part of the concentration-time profile from the time at which the plasma concentrations fell below 0.5 mcg/mL at the descending part of the profile.
If these times fell between 2 observed concentrations, a method of linear interpolation was used for best estimation.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Pharmacokinetics of CP-70429 and PF-03709270 Metabolites
Tidsramme: 0.5, 2, 4, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
PF-03709270 is an oral prodrug of CP-70,429.
Upon oral absorption, PF-03709270 is rapidly hydrolyzed, yielding the active drug CP-70,429 and metabolites.
|
0.5, 2, 4, 8, 12, 24 hours post-dose (for all participants) and 48 hours post-dose (for participants with moderate and severe renal impairment)
|
Concentration Versus Time Summary of 2-Ethylbutyric Acid
Tidsramme: 1, 3, 8 hours post-dose
|
Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =100 ng/mL) to zero.
Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0.
|
1, 3, 8 hours post-dose
|
Concentration Versus Time Summary of Plasma Formate
Tidsramme: 1, 3, 8 hours post-dose
|
Concentration versus time summary was calculated by setting concentration values below the lower limit of quantification (LLQ =100 ng/mL) to zero.
Summary statistics were not to be presented if number of observations above lower limit of quantification (NALQ) =0.
|
1, 3, 8 hours post-dose
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Baseline up to 7-10 days after the last dose of study drug (up to 32 days)
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between first dose of study drug and up to 7-10 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.
|
Baseline up to 7-10 days after the last dose of study drug (up to 32 days)
|
Number of Participants With Laboratory Abnormalities
Tidsramme: Baseline up to 7-10 days after the last dose of study drug (up to 32 days)
|
Criteria for laboratory test abnormality: Hematology (hemoglobin, hematocrit, red blood corpuscles [RBC] count: less than [<]0.8*lower
limit of normal [LLN], platelets: <0.5*LLN/greater than [>]1.75*upper
limit of normal [ULN], leukocytes: <0.6*LLN or >1.5*ULN, lymphocytes, total neutrophils: <0.8*LLN or >1.2*ULN, basophils, eosinophil, monocytes: >1.2*ULN); Liver Function (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: >0.3*ULN, total protein, albumin: <0.8*LLN or >1.2*ULN); total bilirubin, direct bilirubin, indirect bilirubin: >1.5*ULN; Renal Function (blood urea nitrogen, creatinine: >1.3*ULN, uric acid: >1.2*ULN); Electrolytes (sodium: <0.95*LLN or >1.05*ULN, potassium, chloride, calcium, bicarbonate: <0.9*LLN or >1.1*ULN; creatine kinase: >2.0*ULN; glucose fasting: <0.6*LLN or >1.5*ULN, urine white blood corpuscles [WBC] and RBC: greater than or equal to (>=) 6/High Power Field [HPF]).
|
Baseline up to 7-10 days after the last dose of study drug (up to 32 days)
|
Number of Participants With Vital Sign Abnormalities
Tidsramme: Baseline up to 7-10 days after the last dose of study drug (up to 32 days)
|
Criteria for vital signs abnormalities included supine/sitting pulse rate of <40 beats per minute (bpm) or >120 bpm, supine systolic blood pressure (SBP) of <90 millimeter of mercury (mmHg), >=30 mmHg maximum increase and decrease from baseline in same posture, supine diastolic blood pressure (DBP) of <50 mmHg, >=20 mmHg maximum increase and decrease from baseline in same posture, heart rate <=45 beats per minute (bpm) or >=120 bpm or decrease/increase of >=15 bpm.
|
Baseline up to 7-10 days after the last dose of study drug (up to 32 days)
|
Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
Tidsramme: Baseline up to 7-10 days after the last dose of study drug (up to 32 days)
|
Criteria for abnormal ECG (12-lead) values were defined as: maximum PR interval >=300 millisecond (msec) and maximum increase of >=25 percent for baseline value of >200 msec and >=50% for baseline value of <=200 msec for PR interval, QRS interval >=200 msec; QT interval corrected using the Fridericia formula (QTcF) >=500 msec or increase of >45 msec.
|
Baseline up to 7-10 days after the last dose of study drug (up to 32 days)
|
Number of Participants With Change From Baseline in Physical Examinations
Tidsramme: Baseline, 7-10 days after the last dose of study drug
|
Physical examination included examination of the skin, eyes, ears, throat, neck, and cardiac, respiratory, gastrointestinal and musculoskeletal systems.
The examination assessed the participants for any potential changes in physical status, as determined by the investigator.
Any untoward findings identified on physical exams conducted after the administration of the first dose of study medication was captured as an adverse event.
|
Baseline, 7-10 days after the last dose of study drug
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- A8811009
- 2009-017796-20 (EudraCT-nummer)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Lungebetennelse
-
University of KentuckyPfizerFullførtMeticillin-resistent Staphylococcal Aureus PneumoniForente stater
-
Assistance Publique - Hôpitaux de ParisFullførtAlvorlige infeksjoner Pneumoni med invasiv ventilasjon i PICUFrankrike
-
Bandim Health ProjectMedical Research Council Unit, The GambiaFullført
-
Asan Medical CenterFullførtIkke-HIV-pasienter med Pneumocystis Jiroveci PneumoniKorea, Republikken
-
M.D. Anderson Cancer CenterFullførtKreft | Akutt leukemi | Respiratoriske syncytiale virusinfeksjoner | Beinmargstransplantasjonsinfeksjon | Infeksjon hos margtransplantasjonsmottakere | Respiratorisk Syncytial Virus PneumoniForente stater
Kliniske studier på CP-70,429 and PF-03709270
-
PfizerFullførtLungebetennelse, bakteriellForente stater, Australia, Canada, Korea, Republikken, Polen
-
University of HelsinkiFullførtSepsis | Bakteremi | Staphylococcus Aureus | EndokardittFinland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtTilbakevendende ovariekarsinom | HLA-A*0201 Positive celler tilstede | COL6A3 Positiv | PRAME PositivForente stater
-
University of NebraskaNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeHER2 positivt brystkarsinom | Stage I brystkreft AJCC v7 | Stage IA brystkreft AJCC v7 | Stage IB brystkreft AJCC v7 | Trinn II brystkreft AJCC v6 og v7 | Stage IIA brystkreft AJCC v6 og v7 | Stage IIB brystkreft AJCC v6 og v7Forente stater
-
National Cancer Institute (NCI)FullførtStadium II brystkreft | Stadium IIIA Brystkreft | Stadium IA Brystkreft | Stadium IB brystkreft | HER2/Neu PositivForente stater, Puerto Rico
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage IV brystkreft | Stadium IIIA Brystkreft | Stadium IIIB Brystkreft | Stage IIA brystkreft | Stadium IIB brystkreft | Stadium IIIC BrystkreftForente stater
-
Children's Oncology GroupNational Cancer Institute (NCI)FullførtTilbakevendende nevroblastom | Solid neoplasma fra barndommen | Tilbakevendende anaplastisk storcellet lymfom i barndommenForente stater, Canada
-
National Cancer Institute (NCI)NRG OncologyAvsluttetStage IIIA ikke-småcellet lungekreft AJCC v7 | Stage III ikke-småcellet lungekreft AJCC v7 | Stadium IIIB ikke-småcellet lungekreft AJCC v7Forente stater
-
University of NebraskaNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeStadium II brystkreft | Stadium IIIA Brystkreft | Stadium IIIB Brystkreft | Invasivt brystkarsinom | Stadium IA Brystkreft | Stage IIA brystkreft | Stadium IIB brystkreft | Stadium IIIC Brystkreft | Østrogenreseptor negativ | Østrogenreseptor positiv | HER2/Neu negativ | HER2/Neu Positiv | Progesteronreseptor negativ | Progesteronreseptor positiv og andre forholdForente stater
-
National Cancer Institute (NCI)AvsluttetKronisk lymfatisk leukemi | Tilbakevendende lite lymfatisk lymfom | Prolymfocytisk leukemi | Refraktær kronisk lymfatisk leukemi | Stage III lite lymfatisk lymfom | Stage IV lite lymfatisk lymfom | Stadium I Kronisk lymfatisk leukemi | Stadium II Kronisk lymfatisk leukemi | Stage I, lite lymfatisk lymfom | Stadium III Kronisk lymfatisk leukemi og andre forholdForente stater